Background
Phase III, double-blind, placebo-controlled RCT. N=521 women with HR+ HER2- advanced breast cancer progressing on prior endocrine therapy. Pre- and postmenopausal patients enrolled; premenopausal received goserelin. Fulvestrant backbone; palbociclib 125mg d1–21/28.
Interventions and follow up
Arm A: Palbociclib 125mg days 1–21 of 28-day cycle + fulvestrant 500mg IM q28d (+ goserelin if premenopausal)
Arm B: Placebo + fulvestrant 500mg IM q28d (+ goserelin if premenopausal)
Primary endpoint: Progression-free survival (PFS)
mFollow up: 44.8 months (OS analysis)
Arm B: Placebo + fulvestrant 500mg IM q28d (+ goserelin if premenopausal)
Primary endpoint: Progression-free survival (PFS)
mFollow up: 44.8 months (OS analysis)
Results
PFS: 9.5 vs 4.6mo, HR 0.46, 95% CI 0.36–0.59, P<.001
OS (final): 34.9 vs 28.0mo, HR 0.81, 95% CI 0.64–1.03 — not significant
ORR: 19.3% vs 9.4%
OS (final): 34.9 vs 28.0mo, HR 0.81, 95% CI 0.64–1.03 — not significant
ORR: 19.3% vs 9.4%
Adverse events
Hematologic: Grade ≥3 neutropenia 62.0% vs 0.6%; grade ≥3 anemia 3.0%; febrile neutropenia 0.6%
Tolerability: Dose reduction 34.0%; discontinuation 9.4%
Tolerability: Dose reduction 34.0%; discontinuation 9.4%
Conclusions
Palbociclib + fulvestrant significantly improved PFS in HR+ HER2- mBC after prior endocrine therapy. OS did not reach statistical significance at final analysis (34.9 vs 28.0mo; 6.9-month numerical difference, non-significant).
Key Limitations
Lack of OS benefit (consistent with PALOMA-2) is the primary limitation; post-progression therapies likely diluted the signal. Wide OS HR CI (0.64–1.03) leaves open meaningful benefit. Grade ≥3 neutropenia in 62% requires CBC monitoring. Premenopausal subset (goserelin) not stratified for definitive analysis. In the adjuvant CDK4/6i era, this population increasingly has prior CDK4/6i — a setting not addressed by PALOMA-3.
Clinical Context
PALOMA-3 established palbociclib + fulvestrant as a standard second-line option (FDA approved 2016). The negative OS result mirrors PALOMA-2 and contrasts with MONALEESA-3 and MONARCH-2, which showed OS benefits in the same setting. Many oncologists now preferentially choose ribociclib or abemaciclib combinations based on OS data. ESMO-MCBS 3.